MUSC background

MUSC Hollings Cancer Center

Hollings Cancer Center (Director, Andrew Kraft, M.D.) is recognized by U.S. News & World Report as being among the top 25% of cancer programs in the nation and is one of fewer than 70 National Cancer Institute– designated cancer centers in the nation. As one of the leading cancer treatment centers in the Southeast, Hollings Cancer Center combines the full range of cancer specialties, including medical oncology, radiation oncology, and numerous surgical oncology subspecialties. Its multidisciplinary tumor boards enable physicians to share their collective expertise to explore the best treatments for individual patients. Physicians at the Hollings Cancer Center also have daily interactions with more than 100 cancer scientists examining the genetics of cancer, discovering new target cancer therapies and vaccines, as well as identifying new effective cancer prevention and control strategies.

Program Highlights

Cutting-Edge Techniques for Treating Head and Neck Cancer

Head and Neck Tumor Center

The Head and Neck Tumor Center at MUSC is providing comprehensive care to patients and is among the first to offer both transoral robotic surgery and sialendoscopy.

Innovative Treatments for Sarcoma at MUSC

Sarcoma

The Hollings Cancer Center (HCC) at MUSC, one of fewer than 70 National Cancer Institute (NCI)-designated cancer centers in the nation, offers a multidisciplinary, sarcoma-specific tumor board and innovative treatments for sarcoma.

Faculty Leadership

Andrew S. Kraft, M.D.

Andrew S. Kraft, M.D.

Andrew S. Kraft, M.D., is Director of the Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC).

Kevin F. Staveley-O'Carroll, M.D., PhD

Kevin F. Staveley-O'Carroll, M.D., PhD

Kevin F. Staveley-O'Carroll is the Alice Ruth Reeves Folk Endowed Chair in Clinical Oncology and Medical Director of the Oncology Service Line.